<DOC>
	<DOCNO>NCT00109681</DOCNO>
	<brief_summary>The primary purpose study determine whether iloprost inhalation solution safe subject idiopathic pulmonary fibrosis ( IPF ) elevate pulmonary arterial pressure . The secondary purpose evaluate effectiveness treatment subject disease .</brief_summary>
	<brief_title>Inhaled Iloprost Adults With Abnormal Pulmonary Pressure Associated With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>While FDA approve therapy treatment IPF , therapies show effective ameliorating effect pulmonary hypertension patient PAH ( pulmonary arterial hypertension ) , include inhale iloprost . However , therapy use extensively patient IPF pulmonary hypertension complication . The potential benefit treatment pulmonary hypertension complicate IPF include : improvement pulmonary hemodynamics , reduction pulmonary artery pressure pulmonary vascular resistance , increase cardiac output .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Diagnosis idiopathic pulmonary fibrosis accord American Thoracic Society criterion Diagnosis elevate pulmonary pressure Six minute walk distance 50380 NYHA functional class II IV Pulmonary fibrosis relate systemic disorder Significant chronic obstructive pulmonary disease History thromboembolic disease within previous year Awaiting lung transplantation within next 36 week Active lung infection Survival prognosis less 1 year Significant leftsided heart failure , active coronary artery disease Clinically relevant liver disease Concurrent medication : epoprostenol , treprostinil , bosentan , PDE5 inhibitor , investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>ACTIVE</keyword>
	<keyword>iloprost</keyword>
	<keyword>idiopathic pulmonary fibrosis</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
</DOC>